Kallyope

About Kallyope

Kallyope is a neuroscience-focused biopharmaceutical company developing innovative medicines for migraine and metabolic disorders. Leveraging insights into neural signaling pathways, the company is advancing a late-stage pipeline with novel neural circuit targets and a Klarity platform to enable differentiated therapeutics. Headquartered in New York City, Kallyope emphasizes agile drug development led by world-class neuroscientists and experienced drug developers.